News Release

Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently epidemic Omicron sub-variants as booster shot after inactivated vaccine

Peer-Reviewed Publication

Compuscript Ltd

 

https://doi.org/10.1016/j.bsheal.2023.02.002

 

With continuous mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the severe immune escape of Omicron sub-variants urges the development of next-generation broad-spectrum vaccines, especially as booster jabs after high-level vaccination coverage of inactivated vaccines in China and many other countries. Previously, the authors of this article developed a coronavirus disease 2019 (COVID-19) protein subunit vaccine ZF2001® based on the tandem homo-prototype receptor-binding domain (RBD)-dimer of the SARS-CoV-2 spike protein. The antigen was upgraded into a hetero-chimeric prototype (PT)-Beta or Delta-BA.1 RBD-dimer to broaden the cross-protection efficacy and prove its efficiency with protein subunit and mRNA vaccine platforms. Herein, the authors further explore the hetero-chimeric RBD-dimer mRNA vaccines and evaluated their broad-spectrum activities as booster jabs following two doses of inactivated vaccine (IV) in mice. The data demonstrated that the chimeric vaccines significantly boosted neutralizing antibody levels and specific T-cell responses against the variants, and PT-Beta was superior to Delta-BA.1 RBD as a booster in mice, shedding light on the antigen design for the next-generation COVID-19 vaccines.

 

Keywords: SARS-CoV-2. RBD-dimer, mRNA Vaccine, Broad-spectrum, Omicron, BA.5

# # # # # #

 

Biosafety and Health is sponsored by the Chinese Medical Association, managed by National Institute for Viral

Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC).

For more information, please visit https://www.journals.elsevier.com/biosafety-and-health

Editorial Board: https://www.sciencedirect.com/journal/biosafety-and-health/about/editorial-board

Biosafety and Health is available on ScienceDirect (https://www.sciencedirect.com/journal/biosafety-and-health).

Submissions to Biosafety and Health may be made using Editorial Manager®

(https://www.editorialmanager.com/bsheal/default.aspx).

CiteScore: 4.8

ISSN 2590-0536

 

# # # # # #

 

Qian Chen, Pei Du, Yuxuan Han, Xuehui Ma, Rong Zhang, Xiaoyu Rong, Xu Zhao, Renyi Ma, Huiting Yang, Anqi Zheng, Qingrui Huang, Jinghua Yan, Hui Wang, Xin Zhao, Lianpan Dai, George F. Gao, Qihui Wang, Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine, Biosafety and Health, 2023, https://doi.org/10.1016/j.bsheal.2023.02.002


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.